PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Semaglutide is among the most discussed compounds in metabolic disease research globally, and that conversation is very much active in Ireland. For Irish research teams and institutions looking to source semaglutide in Ireland for laboratory and preclinical study, this page provides a full reference covering its pharmacological profile, the research landscape, and how to obtain research-grade material with verified documentation from an Irish supplier.
This is a research reference only. Semaglutide exists as a licensed medicine in several formulations (Ozempic, Wegovy, Rybelsus). Research-grade semaglutide supplied by Peptides Lab Ireland is not a licensed pharmaceutical product — it is supplied exclusively for in-vitro and preclinical laboratory research purposes and must not be used for human administration.
Semaglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist. It is a 31-amino acid peptide analogue of native human GLP-1, modified to extend its half-life through fatty acid conjugation to albumin — giving it a plasma half-life of approximately one week compared to the native peptide’s 1–2 minutes. Its molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉, with a molecular weight of approximately 4,113.6 Da.
Native GLP-1 is secreted by intestinal L-cells in response to food intake and acts on GLP-1 receptors in the pancreas, brain, gut, and other tissues to regulate insulin secretion, glucagon suppression, gastric emptying, and appetite signalling. Semaglutide’s extended half-life makes it a practical tool for studying these pathways in sustained preclinical models.
The primary research application of semaglutide in laboratory settings is the study of metabolic pathways — particularly insulin secretion dynamics, beta-cell function, glucagon suppression, and the GLP-1 receptor signalling cascade. Rodent models of type 2 diabetes and obesity have been extensively used to characterise these mechanisms, with semaglutide becoming a standard tool in this research area.
A significant body of research has focused on semaglutide’s central nervous system effects — specifically its action on hypothalamic circuits regulating appetite and energy expenditure. Studies have examined GLP-1 receptor expression in the arcuate nucleus and downstream effects on food intake and body weight in preclinical models.
Semaglutide has been studied for its effects on hepatic fat accumulation (NASH/MAFLD models), adipose tissue inflammation, and lipid metabolism. Phase 3 clinical trial data for NASH indications has driven renewed interest in understanding the compound’s hepatic mechanisms at the molecular level.
The SUSTAIN and SELECT clinical trial programmes demonstrated cardiovascular outcome benefits with semaglutide. This has generated substantial interest in the underlying cardioprotective mechanisms — GLP-1 receptor expression in cardiac tissue, anti-inflammatory pathways, and effects on endothelial function — which are being studied in preclinical settings.
Peptides Lab Ireland supplies semaglutide with the following documentation on every batch:
Dispatched from within Ireland with cold-chain packaging and tracked delivery. No customs complications for Irish research teams.
No. Ozempic and Wegovy are licensed pharmaceutical products manufactured under GMP conditions for human therapeutic use. Research-grade semaglutide is manufactured to research purity standards for in-vitro and preclinical laboratory study only. It is not a pharmaceutical product and must not be used for human administration.
Research-grade semaglutide — distinct from licensed pharmaceutical formulations — is not a scheduled controlled substance under Irish law. It can be legally purchased for in-vitro laboratory research purposes by qualified researchers. See our guide: Are Peptides Legal in Ireland?
≥98% confirmed by HPLC, with mass spectrometry identity confirmation. All batches supplied by Peptides Lab Ireland are documented to this standard.
Yes — tracked, cold-packaged delivery to all addresses across the Republic of Ireland.
Research-grade semaglutide is supplied by Peptides Lab Ireland for in-vitro laboratory and scientific research purposes only. It is not a licensed medicine for human use. It must not be administered to humans or animals. Peptides Lab Ireland operates in compliance with HPRA guidelines. For medical concerns, consult a qualified healthcare professional.
Receive News
